A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
177estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-03 | actual | When the study began enrolling |
| Primary completion | 2026-03-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-17 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: NNC0174-1213 A
- Drug: Cagrilintide B
- Drug: Placebo A (NNC0174 1213 A)
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213
measured From NNC0174 1213 administration (Day 1) to completion of the end of study visit (Day 46)
Part B: Number of treatment emergent adverse events (TEAE)
measured From first administration (Day 1) to completion of the end of study visit (Day 67)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed